Urogen Pharma Ltd. (URGN) — 10-Q Filings
All 10-Q filings from Urogen Pharma Ltd.. Browse 7 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (7)
- 10-Q Filing — May 6, 2026
-
UroGen Pharma's Losses Widen Amid Soaring Expenses, Cash Drains
— Nov 6, 2025 Risk: high
UroGen Pharma Ltd. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $127.1 million, up from $89.4 million in t -
UroGen Pharma Corrects Q2 2024 EPS, Adjusts Prepaid Obligations
— Aug 7, 2025 Risk: medium
UroGen Pharma Ltd. (URGN) filed its 10-Q for the period ending June 30, 2025, revealing an immaterial correction to its previously reported loss per share for Q -
UroGen Pharma Q1 2025: $100M Assets, $8.8M Net Loss
— May 12, 2025 Risk: medium
UroGen Pharma Ltd. filed its Q1 2025 10-Q report on May 12, 2025, for the period ending March 31, 2025. The company reported total assets of $100 million and to -
UroGen Pharma Q3 2024: Assets $42.2M, Liabilities $32.5M
— Nov 6, 2024 Risk: medium
UroGen Pharma Ltd. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $42.2 million and total liabilities of $32.5 mi -
UroGen Pharma Q2 2024: Assets $614K, Liabilities $65K
— Aug 13, 2024 Risk: low
UroGen Pharma Ltd. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $614,035 and total liabilities of $65,212 for the qu -
UroGen Pharma Ltd. Files 10-Q for Period Ending March 31, 2024
— May 13, 2024 Risk: low
UroGen Pharma Ltd. (URGN) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. UroGen Pharma Ltd. reported Q1 2024 results. Raw materials valued at $0.
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX